|
1 hit(s) found in 0.06 seconds Search term: SNIOPGDIGTZGOP-UHFFFAOYAR Found by InChIKey (full match)
Please
login
to be able to add spectra, identifiers, links and publications.
Glyceryl trinitrate (GTN) is an alternate name for the chemical nitroglycerin, which has been used to treat angina and heart failure since at least 1870. Despite this, the mechanism of nitric oxide (NO) generation from GTN and the metabolic consequences of this bioactivation are still not entirely understood. In medical circles it is often referred to as "nitro."
Read more... or Edit at Wikipedia...
Nitroglycerin ( NG), ( United States spelling) also known as nitroglycerine, ( UK spelling), trinitroglycerin, trinitroglycerine, 1,2,3-trinitroxypropane and glyceryl trinitrate, is a heavy, colorless, oily, explosive liquid obtained by nitrating glycerol. Since the 1860s, it has been used as an active ingredient in the manufacture of explosives, specifically dynamite, and as such is employed in the construction and demolition industries. Similarly, since the 1880s, it has been used by the military as an active ingredient, and a gellatinizer for nitrocellulose, in some solid propellants, such as Cordite and Ballistite.
Nitroglycerin is also used medically as a vasodilator to treat heart conditions, such as angina and chronic heart failure. It is one of the oldest and most useful drugs for treating heart disease by shortening or even preventing attacks of angina pectoris. Nitroglycerin comes in forms of tablets, sprays or patches. Feb97, Vol. 7, Issue 6 An alternative IUPAC name is nitrate.
Read more... or Edit at Wikipedia...
Links & References
|
|
Kenneth E. Thummel and Danny D. Shen.
Peak Time, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023
'Peak-Time' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in hours unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Peak-Time' values indicated for them have been provided in the files here.
Structures (and values) for Clavulanate (1.3), Enoxaparin (3), Epoetin Alfa (SC: 18, IP:12), Etanercept (SC-SD:72(48-96)), Filgrastim (4-5.8), Heparin (3), Interferon Alfa (IM:3.8,SC:7.3), Interferon Beta (SC:1-8), Lithium (IR:0.5-3, SR:2-6), Mycophenolate (MPA: 1.1-2.2), Prednisolone (1.5+-0.5), Sargramostim (A,SC: 1-3, C,SC:1.5-4) and Streptokinase (0.9+-0.21) have not been provided here.
In all, 270 drugs and their 'Peak-Time' values are given in the files here.
|
|
|
|
Kenneth E. Thummel and Danny D. Shen.
Urinary Excretion, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023
Urinary Excretion (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had Urinary Excretion values indicated for them have been provided in the files here.
Structures (and values) for Alteplase (t-PA) (Low), Clavulanate (43+-14), Enoxaparin (43), Epoetin alfa (<3), Etanercept (Negligible), Heparin (Negligible), Lithium (95+-15), Mycophenolate (MPA: <1), Prednisolone (26+-9), Rapacuronium (6-22) and Streptokinase (0) have not been provided here.
In all, 297 drugs and their Urinary Excretion values (%) are given in the files here.
|
|
|
|
Kenneth E. Thummel and Danny D. Shen.
Volume of Distribution, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023
'Volume of Distribution' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in liters/kg units unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Volume of Distribution' values indicated for them have been provided in the files here.
Structures (and values) for Alteplase (t-PA) (0.10+-0.01), Clavulanate (0.21+-0.05), Enoxaparin (0.12+-0.04), Epoetin Alfa (0.033+-0.013 (0.033-0.075)), Etanercept (0.11), Filgrastim (0.15), Heparin (0.058+-0.11) +- 0.1), Infliximab (0.043). Interferon Alfa (0.40+-0.19), Interferon Beta (2.9+-1.8), Lithium (0.66+-0.16), Mycophenolate (MPA: 3.6+-4), Prednisolone (0.42+-0.11), Rapacuronium (0.2-0.5), Sargramostim (A: -, C:2(0.4-18) liters/(m.m)) and Streptokinase (0.08+-0.04) have not been provided here.
In all, 284 drugs and their 'Volume of Distribution' values are given in the files here.
|
|
|
|
Kenneth E. Thummel and Danny D. Shen.
Peak Concentration, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023
'Peak-Concentrations' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. The units are indicated along with the values. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table.
Structures (and values) for Alteplase (t-PA) (973+-133 ng/ml), Clavulanate (2.8 micro g/ml), Enoxaparin (ACLM: 145+-45 ng/ml, BCLM: 414+-87 ng/ml), Epoetin Alfa (SC: 176+-75 U/l, IP: 375+-123 U/l), Etanercept (IV:2.32 micro-g/ml, SC-SD:1.2 micro-g/ml, SC-MD 3 micro-g/ml), Filgrastim (SC: 4 and 49 ng/ml), Heparin (70+-39 ng/ml), Infliximab (118 micro-g/ml), Interferon Alfa (IV: ~13 ng/ml, IM: 2.0 (1.5-2.6) ng/ml, SC: 1.7 (1.2-2.3) ng/ml), Interferon Beta (IV: 1491+-659 IU/ml, SC: 40+-20 IU/ml), Lithium (IR: 1-2 mM, SR: 0.7-1.2 mM), Mycophenolate (MPA: 8-19 micro-g/ml), Prednisolone (458+-150 ng/ml), Rapacuronium (6-20 micro-g/ml), Sargramostim (A, IV: 5ng/ml, A, SC: 1.5 ng/ml, C, IV: 100 ng/ml, C, SC: 10 ng/ml) and Streptokinase (188+-58 IU/ml) have not been provided here.
In all, 304 drugs and their 'Peak-Concentration' values are given in the files here.
|
|
|
|
Kenneth E. Thummel and Danny D. Shen.
Clearance , "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023
'Clearance' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in (ml/min/kg) units unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Clearance' values indicated for them have been provided in the files here.
Structures (and values) for Alteplase (t-PA) (10+-4), Clavulanate (3.6+-1.0), Enoxaparin (0.3+-0.1), Epoetin Alfa (0.047+-0.017 (0.047-0.092)), Etanercept (0.02), Filgrastim (0.5-0.7), Heparin (1/(0.65 + 0/0.008D) +- 0.1), Interferon Alfa (2.8+-0.6), Interferon Beta (13+-5), Lithium (0.35+-0.11), Mycophenolate (MM: 120-163, MPA: 2.5+-0.4), Prednisolone (1.0+-0.16), Rapacuronium (7-11), Sargramostim (A: 420 ml/min/(m.m), C:49(15-118) ml/min/(m.m)) and Streptokinase (1.7+-0.7) have not been provided here.
In all, 301 drugs and their 'Clearance' values are given in the files here.
|
|
|
|
Kenneth E. Thummel and Danny D. Shen.
Percentage Oral Availability, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023
Availability (Oral) % have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had Availability values indicated for them have been provided in the files here.
Structures (and values) for Clavulanate (75+-21), Enoxaparin (SC: 92), Epoetin alfa (SC: 22 (11-36), IP: 3 (1-7)), Etanercept (SC: 58), Filgrastim (SC: 49+-9), Interferon alfa (IM: 80-83, SC: 90), Interferon beta (SC: 51+-17), Lithium (100), Mycophenolate (MM: ~0, MPA: 94) and Prednisolone (82+-13) have not been provided here.
In all, 242 drugs and their Availability (Oral) % are given in the files here.
|
|
275 drugs and their human oral bioavalability values have been given in the supplementary material of the paper. These values have in turn been taken from Goodman & Gilman's The Pharmacological Basis of Therapeutics, VIII and X Editions. The datasets are available from the QSAR World pages: http://www.qsarworld.com/qsar-datasets-veber.php
|
|
Igor V. Tetko, Vsevolod Yu. Tanchuk, Tamara N. Kasheva, and Alessandro E. P. Villa.
Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices, J. Chem. Inf. Comput. Sci., 2001, 41 (6), pp 1488–1493
The molecular weight and electrotopological E-state indices were used to estimate by Artificial Neural Networks aqueous solubility for a diverse set of 1291 organic compounds. The neural network with 33-4-1 neurons provided highly predictive results with r2 = 0.91 and RMS = 0.62.
|
|
|
User Data
- experimental physchem properties
- miscellaneous
-
|
|
Visual appearance of the given substance.
|
 |
-
-
-
-
-
-
-
Validated by Experts, Validated by Users, Non-Validated, Removed by Users,
Redirected by Users, Redirect Approved by Experts
1,2,3-propanetriol, trinitrate
1,2,3-Propanetriyl trinitrate
Aquo-Trinitrosan
Gilucor "Nitro"
Glycerol Nitric Acid Triester
nitran
Nitriderm
Nitro Mack
Nitrolande
Nitrolar
More...
Nitrosigma
Propan-1,2,3-triyltrinitrat
Propane-1,2,3-triyl trinitrate
Reminitrol
S.N.G.
Trinitrate 1,2,3-propanetriol
trinitrate de propane-1,2,3-triyle
Angised
Anogesic
Corangil
Explosive Gum
Gilucor
Glonoine Oil
Glyceroltrinitraat
[Dutch]
Hercol 2
Hercol 2x
Hercon 2
Hercon 2x
Hercosplit WR
Nitric Acid Triester of Glycerol
NitrocapT.D.
Nitroglicerina
[Italian]
Nitrogliceryna
[Polish]
Nitrol Creme
Nitro-Prn
orient oil yellow gg
petrol yellow wt
SNG
Spirits of Nitroglycerin
Sutonit
TNG
Trinitrin Tablets
Unigel
1,2,3-Propanetriol trinatrate
1,2,3-Propanetriol trinitrate
1,2,3-propanetrioltrinitrate
1,2,3-propanetriyl nitrate
1,2,3-trinitrooxypropane
105469-31-6
[RN]
1802063
[Beilstein]
200-240-8
[EINECS/ELINCS]
337376-15-5
[RN]
3-Propanetriol trinitrate; Trinitroglycerine
4-01-00-02762 (Beilstein Handbook Reference)
[Beilstein]
55-63-0
[RN]
80066-48-4
[RN]
8013-23-8
[RN]
9010-02-0
[RN]
Adesitrin
Aldonitrin
Angibid
Anginine
Angiolingual
Angiplex
Anglix
Angonist
Angorin
Aquo-Trimitrosan
Blasting gelatin
Blasting oil
Buccal
[Wiki]
Buccard
Cardabid
Cardamist
Cardinit
Cardiodisco
Cellegesic
Chitamite
Colenitral
Corangin Nitrokapseln
Cordipatch
Corditrine
Coro-Nitro
D005996
Dauxona
Deponit
Deponit 5
Deponit TTS 10
Deponit TTS 5
Deponit-5
Diafusor
Discotrine
Dynamite
Epinitril
Gepan Nitroglicerin
Gilucor nitro
Gilustenon
Glonoin
glycerin trinitrate
Glycerintrinitrate
[Czech]
Glycerintrinitrate [Czech]
Glycerol (trinitrate de)
[French]
glycerol trinitrate
Glycerol trinitrate, Nitroglycerine
Glycerol(trinitrate de)
[French]
glycerol, nitric acid triester
Glyceroltrinitraat [Dutch]
glyceryl trinitrate
Glycerylnitrat
Glytrin
GTN
GTN-Pohl
Herwicard
Herzer
Klavikordal
Lenitral
Lentonitrina
Millisrol
Minitram
Minitran
[Wiki]
Minitran (TN)
Minitro
Mionitrat
Mi-Trates
Myocon
Myoglycerin
Myovin
Natispray
Neos nitro OPT
NG
Niglin
Niglycon
Niong
Niong Retard
Nirmin
Nitora
Nitradisc
Nitradisc Pad
Nitradisc TTS
Nitrangin
Nitrek
Nit-Ret
Nitric acid triester of gylcerol
Nitriderm TTS
Nitrine-TDC
Nitro Bid
Nitro Dur
Nitro Dur TTS
Nitro Mack Retard
Nitro Retard
Nitro Rorer
Nitroard
Nitrobaat
NitroBid
Nitro-Bid
Nitrobid Oint
Nitrobukal
Nitrocap
Nitrocard
Nitrocerin
Nitrocine
Nitrocine 5
Nitroclyn
Nitrocontin
Nitrocontin Continus
NitroCor
Nitrocot
Nitroderm
Nitroderm TTS
Nitroderm TTS Ext
Nitroderm TTS-5
Nitrodisc
NitroDur
Nitro-Dur
Nitro-Dur 10
Nitro-Dur 5
Nitrodyl
Nitrodyl TTS
Nitrogard
Nitrogard-SR
Nitro-Gesanit Retard
Nitroglicerina [Italian]
Nitroglicerina [Spanish]
Nitrogliceryna [Polish]
Nitroglin
Nitroglycerin
[Wiki]
Nitroglycerin (JP15/USP)
Nitroglycerin (NG)
Nitroglycerin [USAN:JAN]
nitroglycerine
[Wiki]
nitroglycerol
[Wiki]
Nitroglyn
Nitroject
Nitrol
Nitrolan
Nitro-lent
Nitroletten
Nitrolin
Nitrolingual
Nitrolingual Spray
Nitrolowe
Nitromack Retard
Nitro-Mack Retard
Nitro-M-Bid
Nitromel
Nitromex
Nitromint
Nitromint Aerosol
Nitromint Retard
Nitromist
Nitronal
Nitronet
Nitrong
Nitrong Retard
Nitrong-SR
Nitro-Par
Nitropatch
Nitropen
Nitropercuten
Nitroperlinit
Nitro-Pflaster
Nitroplast
Nitroprol
Nitropront
Nitroprontan
Nitrorectal
Nitroretard
Nitrorex
Nitrospan
Nitro-span
Nitrostabilin
Nitrostat
Nitro-Time
Nitrovis
Nitrozell retard
NTG
NTS
Nysconitrine
Percutol
Percutol Oint.
Perganit
Perglottal
Perlinganit
Plastranit
Polnitrin
Ratiopharm
[Wiki]
Rectogesic
SK-106N
SN2
Solution glyceryl trinitrate
Soup
Spirit of glonoin
Spirit of glyceryl trinitrate
Spirit of trinitroglycerin
Susadrin
Suscard
Sustac
Sustak
Sustonit
Temponitrin
Top-Nitro
Transderm Nitro
Transderm-N TTS
TRANSDERM-NITRO
Transderm-Nitro TTS
Transiderm-Nitro
Tridil
[Wiki]
Tridil sublin
Trinalgon
Trinipatch
Triniplas
Trinitrate, Glyceryl
Trinitrin
Trinitrina Erba
Trinitrine Simple Laleuf
Trinitroglicerina Fabra
trinitroglycerin
[Wiki]
trinitroglycerol
Trinitrol
Trinitrolong
Trinitron
[Wiki]
Trinitrosan
Turicard
Vasoglyn
Vasolator
Vernies
Willong
Less...
Validated by Experts, Validated by Users, Non-Validated, Removed by Users,
Redirected by Users, Redirect Approved by Experts
|
ACD/LogP: |
2.32
|
# of Rule of 5 Violations: |
1
|
|
ACD/LogD (pH 5.5): |
2.32
|
ACD/LogD (pH 7.4): |
2.32
|
|
ACD/BCF (pH 5.5): |
|
ACD/BCF (pH 7.4): |
|
|
ACD/KOC (pH 5.5): |
|
ACD/KOC (pH 7.4): |
|
|
#H bond acceptors: |
12
|
#H bond donors: |
0
|
|
#Freely Rotating Bonds: |
8
|
Polar Surface Area: |
165.15
Å2
|
|
Index of Refraction: |
1.488
|
Molar Refractivity: |
39.2
cm3
|
|
Molar Volume: |
135.8
cm3
|
Polarizability: |
15.54
10-24cm3
|
|
Surface Tension: |
63.5
dyne/cm
|
Density: |
1.671
g/cm3
|
|
Flash Point: |
145.7
°C
|
Enthalpy of Vaporization: |
51.41
kJ/mol
|
|
Boiling Point: |
295.8
°C at 760 mmHg
|
Vapour Pressure: |
0.00263
mmHg at 25°C
|
Log Octanol-Water Partition Coef (SRC):
Log Kow (KOWWIN v1.67 estimate) = 1.51
Log Kow (Exper. database match) = 1.62
Exper. Ref: Hansch,C et al. (1995)
Boiling Pt, Melting Pt, Vapor Pressure Estimations (MPBPWIN v1.42):
Boiling Pt (deg C): 281.84 (Adapted Stein & Brown method)
Melting Pt (deg C): 50.21 (Mean or Weighted MP)
VP(mm Hg,25 deg C): 0.0272 (Mean VP of Antoine & Grain methods)
MP (exp database): 13.5 deg C
BP (exp database): 250 deg C
VP (exp database): 4.00E-04 mm Hg at 25 deg C
Water Solubility Estimate from Log Kow (WSKOW v1.41):
Water Solubility at 25 deg C (mg/L): 1305
log Kow used: 1.62 (expkow database)
no-melting pt equation used
Water Sol (Exper. database match) = 1380 mg/L (20 deg C)
Exper. Ref: SEIDELL,A (1941)
Water Sol Estimate from Fragments:
Wat Sol (v1.01 est) = 1409.1 mg/L
Wat Sol (Exper. database match) = 1380.00
Exper. Ref: SEIDELL,A (1941)
ECOSAR Class Program (ECOSAR v0.99h):
Class(es) found:
Neutral Organics
Henrys Law Constant (25 deg C) [HENRYWIN v3.10]:
Bond Method : 2.54E-009 atm-m3/mole
Group Method: Incomplete
Exper Database: 9.87E-08 atm-m3/mole
Henrys LC [VP/WSol estimate using EPI values]: 6.228E-006 atm-m3/mole
Log Octanol-Air Partition Coefficient (25 deg C) [KOAWIN v1.10]:
Log Kow used: 1.62 (exp database)
Log Kaw used: -5.394 (exp database)
Log Koa (KOAWIN v1.10 estimate): 7.014
Log Koa (experimental database): None
Probability of Rapid Biodegradation (BIOWIN v4.10):
Biowin1 (Linear Model) : 0.6394
Biowin2 (Non-Linear Model) : 0.4462
Expert Survey Biodegradation Results:
Biowin3 (Ultimate Survey Model): 2.6973 (weeks-months)
Biowin4 (Primary Survey Model) : 3.5201 (days-weeks )
MITI Biodegradation Probability:
Biowin5 (MITI Linear Model) : 0.0847
Biowin6 (MITI Non-Linear Model): 0.0366
Anaerobic Biodegradation Probability:
Biowin7 (Anaerobic Linear Model): 0.7222
Ready Biodegradability Prediction: NO
Hydrocarbon Biodegradation (BioHCwin v1.01):
Structure incompatible with current estimation method!
Sorption to aerosols (25 Dec C)[AEROWIN v1.00]:
Vapor pressure (liquid/subcooled): 0.0533 Pa (0.0004 mm Hg)
Log Koa (Koawin est ): 7.014
Kp (particle/gas partition coef. (m3/ug)):
Mackay model : 5.62E-005
Octanol/air (Koa) model: 2.54E-006
Fraction sorbed to airborne particulates (phi):
Junge-Pankow model : 0.00203
Mackay model : 0.00448
Octanol/air (Koa) model: 0.000203
Atmospheric Oxidation (25 deg C) [AopWin v1.92]:
Hydroxyl Radicals Reaction:
OVERALL OH Rate Constant = 1.0980 E-12 cm3/molecule-sec
Half-Life = 9.741 Days (12-hr day; 1.5E6 OH/cm3)
Half-Life = 116.891 Hrs
Ozone Reaction:
No Ozone Reaction Estimation
Fraction sorbed to airborne particulates (phi): 0.00325 (Junge,Mackay)
Note: the sorbed fraction may be resistant to atmospheric oxidation
Soil Adsorption Coefficient (PCKOCWIN v1.66):
Koc : 130.8
Log Koc: 2.117
Aqueous Base/Acid-Catalyzed Hydrolysis (25 deg C) [HYDROWIN v1.67]:
Rate constants can NOT be estimated for this structure!
Bioaccumulation Estimates from Log Kow (BCFWIN v2.17):
Log BCF from regression-based method = 0.547 (BCF = 3.527)
log Kow used: 1.62 (expkow database)
Volatilization from Water:
Henry LC: 9.87E-008 atm-m3/mole (Henry experimental database)
Half-Life from Model River: 8941 hours (372.5 days)
Half-Life from Model Lake : 9.766E+004 hours (4069 days)
Removal In Wastewater Treatment:
Total removal: 2.02 percent
Total biodegradation: 0.09 percent
Total sludge adsorption: 1.92 percent
Total to Air: 0.01 percent
(using 10000 hr Bio P,A,S)
Level III Fugacity Model:
Mass Amount Half-Life Emissions
(percent) (hr) (kg/hr)
Air 0.873 234 1000
Water 32.5 900 1000
Soil 66.6 1.8e+003 1000
Sediment 0.0884 8.1e+003 0
Persistence Time: 1.06e+003 hr
Descriptors:
0, 0, 0, 0, 0, 0, 0, 6, 12, 0, 0, 0, 0, 0, 5, 0, 0, 9, 0, 0, 0, 0, 0, 0
| Category | Target | PDB Code | LASSO Score |
| Metalloenzymes | ACE, angiotensin-converting enzyme | 1o86 | 0.61 |
| Other Enzymes | AmpC, AmpC beta-lactamase | 1xgj | 0.11 |
| Other Enzymes | HIVPR, HIV protease | 1hpx | 0.11 |
| Nuclear Hormone Receptors | PPARg, peroxisome proliferator activated receptor | 1fm9 | 0.09 |
| Serine Proteases | FXa, factor Xa | 1f0r | 0.05 |
| Other Enzymes | HMGR, hydroxymethylglutaryl-CoA reductase | 1hw8 | 0.03 |
| Other Enzymes | AChE, acetylcholinesterase | 1eve | 0.03 |
| Other Enzymes | COX-2, cyclooxygenase-2 | 1cx2 | 0.01 |
| Kinases | SRC, tyrosine kinase SRC | 2src | 0.01 |
| Nuclear Hormone Receptors | MR, mineralocorticoid receptor | 2aa2 | 0.01 |
| Other Enzymes | GPB, glycogen phosphorylase | 1a8i | 0.01 |
| Nuclear Hormone Receptors | ER, estrogen receptor; agonist | 1l2i | 0.00 |
| Serine Proteases | Thrombin | 1ba8 | 0.00 |
| Nuclear Hormone Receptors | PR, progesterone receptor | 1sr7 | 0.00 |
| Folate Enzymes | DHFR, dihydrofolate reductase | 3dfr | 0.00 |
| Other Enzymes | HIVRT, HIV reverse transcriptase | 1rt1 | 0.00 |
| Other Enzymes | PNP, purine nucleoside phosphorylase | 1b8o | 0.00 |
| Kinases | VEGFr2, vascular endothelial growth factor receptor | 1vr2 | 0.00 |
| Metalloenzymes | COMT, catechol O-methyltransferase | 1h1d | 0.00 |
| Kinases | FGFr1, fibroblast growth factor receptor kinase | 1agw | 0.00 |
| Kinases | TK, thymidine kinase | 1kim | 0.00 |
| Nuclear Hormone Receptors | AR, androgen receptor | 1xq2 | 0.00 |
| Kinases | CDK2, cyclindependent kinase 2 | 1ckp | 0.00 |
| Folate Enzymes | GART, glycinamide ribonucleotide transformylase | 1c2t | 0.00 |
| Kinases | PDGFrb, platelet derived growth factor receptor kinase | N/A | 0.00 |
| Other Enzymes | PARP, poly(ADP-ribose) polymerase | 1efy | 0.00 |
| Other Enzymes | NA, neuraminidase | 1a4g | 0.00 |
| Kinases | HSP90, human heat shock protein 90 | 1uy6 | 0.00 |
| Metalloenzymes | ADA, adenosine deaminase | 1stw | 0.00 |
| Kinases | EGFr, epidermal growth factor receptor | 1m17 | 0.00 |
| Kinases | P38 MAP, P38 mitogen activated protein | 1kv2 | 0.00 |
| Nuclear Hormone Receptors | RXRa, retinoic X receptor R | 1mvc | 0.00 |
| Other Enzymes | SAHH, S-adenosyl-homocysteine hydrolase | 1a7a | 0.00 |
|
|